DIABETIC NEPHROPATHY: Nonsteroidal MRA added to RAS blockade reduces albuminuria

    loading  Checking for direct PDF access through Ovid


A new study reports that addition of the nonsteroidal mineralocorticoid receptor antagonist finerenone to renin-angiotensin system (RAS) blockade resulted in a reduction in albuminuria in patients with diabetic nephropathy. Such a strategy might provide an opportunity to maximize the beneficial effects of RAS blockade without increasing the risk of hyperkalaemia.

Related Topics

    loading  Loading Related Articles